THE INTERNATIONAL SOCIETY OF

Today marks a turning point for people living with focal segmental glomerulosclerosis (FSGS). More than a hundred years after the disease was first defined, the U.S. Food and Drug Administration (FDA) has granted its first ever approval of ...

The recent vasculitis conference delivered important advances in classification, pathogenesis, therapeutics, and precision medicine in ANCA-associated vasculitis (AAV) and related glomerular diseases. Below is a synthesis of key ...

The PARASOL APOL1 Interim Meeting brought together clinicians, statisticians, trialists, industry partners, patients, regulators, and advocates from around the world to accelerate solutions for APOL1 kidney disease. Across two days of ...